Kimia Farma Tbk PT operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kimia Farma Tbk PT with three other
pharmaceutical manufacturers in Asia:
Tianjin Chase Sun Pharmaceutical Company Limited
sales of 5.00 billion Chinese Renmimbi [US$712.77 million]
of which 54%
Shanxi Zhendong Pharmaceutical Co Ltd
(4.40 billion Chinese Renmimbi [US$626.69 million]
of which 107%
was Medicine Manufacture and Sale), and
JW Holdings Corporation
based in KOREA (SOUTH)
(726.42 billion Korean Won [US$609.47 million]
of which 115%
Kimia Farma Tbk PT reported sales of 9.40 trillion Indonesian Rupiahs (US$648.64 million)
December of 2019.
increase of 26.1%
versus 2018, when the company's sales were 7.45 trillion Indonesian Rupiahs .
Sales at Kimia Farma Tbk PT have increased during each of the previous five years
(and since 2014, sales have increased a total of 108%).
Sales of Manufacturing saw an increase
that was more than double the company's growth rate: sales were up
321.0% in 2019, from
272.12 billion Indonesian Rupiahs to 1.15 trillion Indonesian Rupiahs .
Kimia Farma Tbk PT also saw significant increases in sales in
Other (up 40.8% to 180.10 billion Indonesian Rupiahs )